Leo Ehrlich has said that he didn't want to be run

Leo Ehrlich has said that he didn't want to be running a pharmaceutical company, that what he wanted was to focus on research and then license stuff out. But it may be that he's going to want to wait to license Prurisol until they have the dosage tweaked -- the closer you get to FDA approval, the higher price you can command. It shouldn't be very expensive to run the next batch of Prurisol testing. The advantage of testing a dermatological drug is that the results are literally visible and measurable. Something like cancer that takes much longer to be sure of results, and needs expensive tests like MRI's and blood tests and biopsies etc -- those trials are much more expensive to run. Eyeballing a lesion, not so much.